COVID-19, host response treatment, and the need for political leadership

Fedson, David S.

doi:10.1057/s41271-020-00266-7

Cited by 14 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Observational studies and RCTs both have their places in the hierarchy of research designs. 95 However, if there are no RCTs, 96 physicians and health officials will be forced to consider the trade-off between pandemic learning and doing. 97 In this circumstance, they might have to rely on well-conducted observational studies alone to determine whether combination treatment of the host response in COVID-19 patients is effective.…”

Section: Discussionmentioning

confidence: 99%

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Byttebier¹,

Belmans²,

Alexander

et al. 2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR = 0.33; 95% CI 0.17–0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.

show abstract

Section: Discussionmentioning

confidence: 99%

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Byttebier¹,

Belmans²,

Alexander

et al. 2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Observational studies and RCTs both have their places in the hierarchy of research designs [95]. However, if there are no RCTs [96], physicians and health officials will be forced to consider the trade-off between pandemic learning and doing [97]. In this circumstance, they might have to rely on well-conducted observational studies alone to determine whether combination treatment of the host response in COVID-19 patients is effective [98].…”

Section: Discussionmentioning

confidence: 99%

Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs

Byttebier¹,

Belmans²,

Alexander³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise relief to people who live in high-income countries, although vaccines and expensive new treatments are unlikely to arrive in time to help people who live in low-and middle-income countries. The pathogenesis of COVID-19 is characterized by endothelial dysfunction. Several widely available drugs like statins, ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have immunometabolic activities that (among other things) maintain or restore endothelial cell function. For this reason, we undertook an observational study in four Belgian hospitals to determine whether in-hospital treatment with these drugs could improve survival in 959 COVID-19 patients. We found that treatment with statins and ACEIs/ARBs reduced 28-day mortality in hospitalized COVID-19 patients. Moreover, combination treatment with these drugs resulted in a 3-fold reduction in the odds of hospital mortality (OR=0.33; 95% CI 0.17-0.69). These findings were in general agreement with other published studies. Additional observational studies and clinical trials are needed to convincingly show that in-hospital treatment with statins, ACEIs/ARBs, and especially their combination saves lives.

show abstract

“…They would be available on the first pandemic day in any country with a basic healthcare system. 6 Several generic drugs already meet these criteria.…”

mentioning

confidence: 99%